MedPath

Cinacalcet

Generic Name
Cinacalcet
Brand Names
Mimpara, Sensipar, Cinacalcet Mylan, Cinacalcet Accordpharma
Drug Type
Small Molecule
Chemical Formula
C22H22F3N
CAS Number
226256-56-0
Unique Ingredient Identifier
UAZ6V7728S
Background

Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure.

Indication

For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Associated Conditions
Hypercalcemia, Secondary Hyperparathyroidism (SHPT)
Clinical Trials
Related News

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

Phase 4
Completed
Conditions
Kidney Disease
Secondary Hyperparathyroidism
Chronic Kidney Disease
First Posted Date
2005-08-22
Last Posted Date
2009-02-13
Lead Sponsor
Amgen
Target Recruit Count
300
Registration Number
NCT00132431

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

Phase 3
Completed
Conditions
Secondary Hyperparathyroidism
End Stage Renal Disease
Interventions
First Posted Date
2005-07-04
Last Posted Date
2013-05-23
Lead Sponsor
Amgen
Target Recruit Count
673
Registration Number
NCT00117052

Cinacalcet Study to Reach Kidney Disease Outcomes Quality Initiative (K/DOQI) Levels

Phase 2
Completed
Conditions
End Stage Renal Disease
First Posted Date
2005-06-13
Last Posted Date
2013-05-13
Lead Sponsor
Amgen
Registration Number
NCT00113958

Research Study Evaluating Cinacalcet for Patients With End Stage Renal Disease (ESRD)

Phase 2
Completed
Conditions
End Stage Renal Disease
First Posted Date
2005-06-13
Last Posted Date
2013-05-13
Lead Sponsor
Amgen
Target Recruit Count
360
Registration Number
NCT00113945

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

Phase 2
Completed
Conditions
End Stage Renal Disease
First Posted Date
2005-05-17
Last Posted Date
2010-04-23
Lead Sponsor
Amgen
Target Recruit Count
850
Registration Number
NCT00110929

A Research Study for Patients With End-Stage Renal Disease (ESRD)

Phase 4
Completed
Conditions
End Stage Renal Disease
Interventions
Other: Standard of care
First Posted Date
2005-05-17
Last Posted Date
2011-03-07
Lead Sponsor
Amgen
Target Recruit Count
552
Registration Number
NCT00110890

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Phase 3
Completed
Conditions
Kidney Disease
Chronic Kidney Disease
First Posted Date
2004-10-20
Last Posted Date
2013-05-08
Lead Sponsor
Amgen
Target Recruit Count
400
Registration Number
NCT00094484

A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

Phase 3
Completed
Conditions
Secondary Hyperparathyroidism
End Stage Renal Disease
Interventions
Drug: Placebo
First Posted Date
2002-08-06
Last Posted Date
2013-05-08
Lead Sponsor
Amgen
Target Recruit Count
380
Registration Number
NCT00042653

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Phase 2
Completed
Conditions
Secondary Hyperparathyroidism
Chronic Renal Insufficiency
Interventions
First Posted Date
2002-08-01
Last Posted Date
2013-05-13
Lead Sponsor
Amgen
Target Recruit Count
54
Registration Number
NCT00042432

A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer

Phase 4
Completed
Conditions
Hyperparathyroidism
Parathyroid Neoplasms
First Posted Date
2002-05-20
Last Posted Date
2013-05-08
Lead Sponsor
Amgen
Target Recruit Count
46
Registration Number
NCT00037518
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy